Abstract
Recently Alvin Feinstein noted that “In our current patterns of thinking the explanatory pathophysiolgic work is usually regarded as basic biomedical science; the interventional clinical work as art.” (1). Until clinical medicine decisions that are managerial in nature (interventions that maintain or restore health) are based on the same scientific rationale as an in vitro study, for example, and are regarded as the same we will always have difficulty in successfully transferring ideas into useful medical practice. Such has often been the case with biochemical modulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Feinstein AR: Additional basic approaches in clinical research. Clin. Res. 33: 111–114, 1985.
Bertino JR, Mini E, Fernandes DJ: Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy. Seminars in Oncol. 0: 2–5, 1983.
Pitman SW, Kowal CD, Bertino JR: Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer. Seminars in Oncol. 10: 15–19, 1983.
Ringborg U, Ewert G, Kinnman J et al: Methotrexate and 5-fluorouracil in head and neck cancer. Seminars in Oncol. 10: 20–22, 1983.
Browman GP, Archibald SD, Young JEM et al: Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-Fluorouracil in advanced and recurrent squamous cell head and neck cancer. J. of Clin. Oncol. 1: 787–792, 1983.
Blumenreich MS, Woodcock TM, Allegra M et al: Sequential therapy with methotrexate (MTX) and 5-fluorouracil (5-FU) for adenocarcinoma of the colon. Proc. of ASCO 1: 102, 1982.
Bruckner HW, Cohen J: MTX/5FU in trials in gastrointestinal and other cancers. Seminars in Oncol. 10: 32–39, 1983.
Burnett R, Smith F, Hoerni B et al: Sequential methotrexate-5-fluorouracil in advanced measurable colorectal cancer: Lack of appreciable therapeutic synergism. Proc. of AACR 22: 370, 1981.
Drapkin R, Griffiths E, McAloon E et al: Sequential methotrexate (MTX) and 5-fluorouracil (5-FU) in adenocarcinoma of the colon and rectum. Proc. of ASCO 22: 453, 1981.
Herrmann R, Manegold C, Rittinghause R et al: Sequential methotrexate (MTX) and 5-fluorouracil (FU) in colorectal adenocarcinoma: Results of a pilot study. Proc. of ASCO 22: 457, 1981.
Herrmann R, Manegold C, Fritze D et al: Sequential methotrexate and 5-fluorouracil (FU) in gastrointestinal adenocarcinoma and breast cancer. UICC Conference on Clinical Oncology, Lausanne Switzerland, October 1981, p. 131.
Ignoffo RJ, Friedman MA, Reynolds RD et al: Treatment of advanced large bowel carcinoma with sequential methotrexate (MTX), leucovorin (LR) plus Mitomycin C (MMC). Proc. of ASCO 22: 452, 1981.
Kemeny N, Michaelson R: Phase II trial of low-dose methotrexate and sequential 5-fluorouracil in the treatment of metastatic colorectal carcinoma. Proc. of ASCO 1: 95, 1982.
Mehotra S, Rosenthal CJ, Gardner B: Biochemical modulation of antineoplastic response in colorectal carcinoma: 5-Fluorouracil (F), high dose methotrexate (M) with calcium leucovorin (L) rescue (FML) in two sequences of administration. Proc. of ASCO 1: 100, 1982.
Panasci L, Margolese R: Sequential methotrexate (MTX) and 5-fluorouracil (FU) in breast and colorectal cancer: Results of increasing the dose of FU. Proc. of ASCO 1: 101, 1982.
Solan A, Vogl SE, Kaplan BH et al: Sequential chemotherapy of advanced colorectal cancer with a standard or high-dose methotrexate (MTX) followed by 5-fluorouracil. Med. Pediatr. Oncol. 10: 145–149, 1982.
Tisman G, Wu SJG: Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic carcinoma of the colon. Cancer Treat. Rep. 64: 829–835, 1980.
Weinerman B, Schacter B, Schipper H et al: Sequential methotrexate and 5-FU in the treatment of colorectal cancer. Cancer Treat. Rep. 66: 1553–1555, 1982.
Benz C, Schoenberg M, Choti M, Cadman E: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J. Clin. Invest. 66: 1162–1165, 1980.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Baker, L.H. (1986). Problems in the Clinical Evaluation of Biochemical Modulation Therapy. In: Valeriote, F.A., Baker, L.H. (eds) Biochemical Modulation of Anticancer Agents: Experimental and Clinical Approaches. Developments in Oncology, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2331-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2331-0_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9432-0
Online ISBN: 978-1-4613-2331-0
eBook Packages: Springer Book Archive